# OnCo record trilaciclib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trilaciclib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trilaciclib" ;
  schema:name "Trilaciclib"@en ;
  schema:alternateName "G1T28"@en, "Cosela" ;
  schema:description "Trilaciclib is given as an infusion just before chemotherapy for small cell lung cancer to put the bone marrow's stem cells briefly to sleep, so fewer are killed and patients need fewer transfusions and growth factor injections."@en ;
  schema:url <https://onco.cc/drugs/trilaciclib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trilaciclib> ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214200>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=trilaciclib>, <https://en.wikipedia.org/wiki/Trilaciclib> ;
  onco:status "approved" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Intravenous CDK4/6 inhibitor given before chemotherapy to protect bone marrow" ;
  onco:approval "US 2021: To decrease chemotherapy-induced myelosuppression in adults receiving platinum-etoposide or topotecan for extensive-stage small cell lung cancer" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/topotecan/> ;
  onco:companies <https://onco.cc/companies/g1-therapeutics/>, <https://onco.cc/companies/pharmacosmos/> ;
  onco:trials <https://onco.cc/trials/nct07473128/> .